Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging, Cine | 85 | 2024 | 1061 | 11.360 |
Why?
|
Myocardial Ischemia | 45 | 2024 | 2133 | 5.200 |
Why?
|
Myocardium | 51 | 2024 | 4746 | 5.100 |
Why?
|
Myocardial Perfusion Imaging | 27 | 2023 | 659 | 4.860 |
Why?
|
Gadolinium | 29 | 2023 | 961 | 4.650 |
Why?
|
Cardiomyopathies | 40 | 2024 | 2021 | 4.440 |
Why?
|
Myocarditis | 22 | 2024 | 792 | 4.270 |
Why?
|
Ventricular Remodeling | 27 | 2024 | 1270 | 4.140 |
Why?
|
Coronary Artery Disease | 57 | 2024 | 6506 | 3.740 |
Why?
|
Ventricular Function, Left | 52 | 2024 | 3899 | 3.670 |
Why?
|
Contrast Media | 60 | 2024 | 5311 | 3.590 |
Why?
|
Magnetic Resonance Imaging | 121 | 2024 | 36415 | 3.420 |
Why?
|
Myocardial Infarction | 44 | 2024 | 11476 | 3.210 |
Why?
|
Predictive Value of Tests | 105 | 2024 | 15308 | 3.050 |
Why?
|
Heart Ventricles | 30 | 2024 | 3813 | 2.240 |
Why?
|
Gadolinium DTPA | 20 | 2019 | 823 | 2.220 |
Why?
|
Cardiac Imaging Techniques | 14 | 2021 | 278 | 2.210 |
Why?
|
Cardiomyopathy, Dilated | 7 | 2019 | 832 | 2.110 |
Why?
|
Cardiomyopathy, Hypertrophic | 20 | 2024 | 1312 | 1.910 |
Why?
|
Amyloidosis | 16 | 2022 | 865 | 1.880 |
Why?
|
Heart Diseases | 16 | 2023 | 2795 | 1.870 |
Why?
|
Stroke Volume | 41 | 2023 | 5521 | 1.830 |
Why?
|
Fatty Acids, Omega-3 | 5 | 2024 | 1390 | 1.740 |
Why?
|
Heart Atria | 13 | 2022 | 1349 | 1.720 |
Why?
|
Cicatrix | 8 | 2022 | 793 | 1.670 |
Why?
|
Fractional Flow Reserve, Myocardial | 10 | 2022 | 345 | 1.660 |
Why?
|
Coronary Circulation | 21 | 2020 | 1611 | 1.630 |
Why?
|
Fibrosis | 18 | 2024 | 2052 | 1.560 |
Why?
|
Atrial Function, Left | 4 | 2015 | 185 | 1.550 |
Why?
|
Prognosis | 79 | 2024 | 29688 | 1.470 |
Why?
|
Death, Sudden, Cardiac | 14 | 2023 | 1560 | 1.450 |
Why?
|
Coronary Angiography | 31 | 2023 | 4507 | 1.410 |
Why?
|
Exercise Test | 19 | 2024 | 2165 | 1.410 |
Why?
|
Heart Failure | 27 | 2024 | 11701 | 1.340 |
Why?
|
Magnetic Resonance Spectroscopy | 25 | 2023 | 3770 | 1.330 |
Why?
|
Electrocardiography | 30 | 2024 | 6387 | 1.200 |
Why?
|
Chest Pain | 7 | 2022 | 1097 | 1.200 |
Why?
|
Coronary Vessel Anomalies | 2 | 2023 | 307 | 1.160 |
Why?
|
Pulmonary Veins | 5 | 2014 | 743 | 1.050 |
Why?
|
Coronary Vessels | 14 | 2024 | 3111 | 1.010 |
Why?
|
Vasodilator Agents | 8 | 2019 | 989 | 1.000 |
Why?
|
Humans | 311 | 2024 | 761222 | 0.980 |
Why?
|
Image Interpretation, Computer-Assisted | 11 | 2024 | 3366 | 0.980 |
Why?
|
Tachycardia, Ventricular | 6 | 2023 | 1305 | 0.970 |
Why?
|
Atrial Fibrillation | 11 | 2021 | 5114 | 0.960 |
Why?
|
Risk Assessment | 40 | 2024 | 24022 | 0.880 |
Why?
|
Image Enhancement | 8 | 2021 | 2888 | 0.860 |
Why?
|
Catheter Ablation | 8 | 2021 | 2751 | 0.830 |
Why?
|
Coronary Sinus | 3 | 2018 | 84 | 0.790 |
Why?
|
Hypertrophy, Left Ventricular | 10 | 2021 | 854 | 0.780 |
Why?
|
Biofuels | 1 | 2021 | 42 | 0.780 |
Why?
|
Echocardiography | 24 | 2021 | 5006 | 0.770 |
Why?
|
Magnetic Resonance Angiography | 11 | 2020 | 1432 | 0.760 |
Why?
|
Middle Aged | 129 | 2024 | 220858 | 0.760 |
Why?
|
Ventricular Dysfunction, Left | 9 | 2015 | 2131 | 0.740 |
Why?
|
Arrhythmias, Cardiac | 8 | 2023 | 2247 | 0.740 |
Why?
|
Ventricular Function | 4 | 2016 | 406 | 0.730 |
Why?
|
Positron-Emission Tomography | 21 | 2022 | 6586 | 0.720 |
Why?
|
Male | 159 | 2024 | 360703 | 0.720 |
Why?
|
Female | 163 | 2024 | 392552 | 0.720 |
Why?
|
Coronary Disease | 11 | 2023 | 5921 | 0.690 |
Why?
|
Extracellular Matrix | 5 | 2014 | 1720 | 0.670 |
Why?
|
Tissue Survival | 4 | 2020 | 120 | 0.660 |
Why?
|
Aged | 102 | 2024 | 169292 | 0.660 |
Why?
|
Fatty Acid Desaturases | 1 | 2019 | 101 | 0.650 |
Why?
|
Myocardial Contraction | 8 | 2024 | 1516 | 0.640 |
Why?
|
Anthracyclines | 3 | 2023 | 285 | 0.630 |
Why?
|
Ethylene Glycols | 4 | 2024 | 196 | 0.620 |
Why?
|
Risk Factors | 44 | 2024 | 74241 | 0.590 |
Why?
|
Cardiology | 8 | 2023 | 1693 | 0.560 |
Why?
|
Amyloid Neuropathies, Familial | 2 | 2023 | 166 | 0.550 |
Why?
|
Heart Neoplasms | 5 | 2019 | 364 | 0.540 |
Why?
|
Acute Coronary Syndrome | 4 | 2024 | 2194 | 0.530 |
Why?
|
Immunoglobulin Light Chains | 3 | 2024 | 286 | 0.520 |
Why?
|
Sarcomeres | 3 | 2014 | 371 | 0.520 |
Why?
|
Myocardial Revascularization | 8 | 2020 | 794 | 0.520 |
Why?
|
Artificial Intelligence | 6 | 2024 | 2576 | 0.520 |
Why?
|
Tomography, X-Ray Computed | 23 | 2023 | 20588 | 0.520 |
Why?
|
Esters | 1 | 2017 | 210 | 0.510 |
Why?
|
Pericardium | 5 | 2017 | 674 | 0.500 |
Why?
|
American Heart Association | 7 | 2023 | 1043 | 0.500 |
Why?
|
Perfusion | 5 | 2023 | 1390 | 0.490 |
Why?
|
Severity of Illness Index | 22 | 2024 | 15841 | 0.490 |
Why?
|
Climate Change | 1 | 2021 | 498 | 0.490 |
Why?
|
Sarcoidosis | 6 | 2019 | 537 | 0.480 |
Why?
|
Prealbumin | 3 | 2023 | 247 | 0.480 |
Why?
|
Coronary Stenosis | 4 | 2017 | 802 | 0.470 |
Why?
|
Prospective Studies | 39 | 2024 | 54437 | 0.470 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2024 | 629 | 0.470 |
Why?
|
Aniline Compounds | 4 | 2024 | 1073 | 0.460 |
Why?
|
Adiponectin | 1 | 2019 | 1107 | 0.450 |
Why?
|
Microcirculation | 4 | 2014 | 1280 | 0.440 |
Why?
|
Dobutamine | 2 | 2011 | 116 | 0.440 |
Why?
|
Cardiac Volume | 1 | 2013 | 197 | 0.420 |
Why?
|
Amyloid | 2 | 2018 | 848 | 0.420 |
Why?
|
Diabetic Angiopathies | 3 | 2017 | 805 | 0.420 |
Why?
|
Reproducibility of Results | 32 | 2024 | 20118 | 0.410 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2013 | 1724 | 0.410 |
Why?
|
Echocardiography, Doppler | 4 | 2020 | 898 | 0.410 |
Why?
|
Spironolactone | 4 | 2023 | 412 | 0.400 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2020 | 2254 | 0.400 |
Why?
|
Follow-Up Studies | 27 | 2024 | 39127 | 0.400 |
Why?
|
Radionuclide Imaging | 3 | 2021 | 1989 | 0.400 |
Why?
|
Cardiomegaly | 2 | 2014 | 590 | 0.400 |
Why?
|
Aortic Valve Insufficiency | 1 | 2016 | 576 | 0.390 |
Why?
|
Radiopharmaceuticals | 10 | 2024 | 2684 | 0.390 |
Why?
|
Molecular Imaging | 3 | 2019 | 818 | 0.390 |
Why?
|
Defibrillators, Implantable | 5 | 2021 | 1492 | 0.390 |
Why?
|
Iron Overload | 5 | 2012 | 239 | 0.380 |
Why?
|
Heart Transplantation | 5 | 2024 | 3258 | 0.380 |
Why?
|
Leptin | 1 | 2019 | 1595 | 0.380 |
Why?
|
Rubidium Radioisotopes | 6 | 2013 | 97 | 0.370 |
Why?
|
Cardiotonic Agents | 2 | 2011 | 540 | 0.370 |
Why?
|
Time Factors | 27 | 2024 | 39957 | 0.370 |
Why?
|
Brain Abscess | 1 | 2011 | 120 | 0.360 |
Why?
|
Vena Cava, Superior | 1 | 2011 | 196 | 0.360 |
Why?
|
Adult | 63 | 2024 | 221120 | 0.360 |
Why?
|
Heart Septum | 2 | 2009 | 301 | 0.360 |
Why?
|
Technology Assessment, Biomedical | 1 | 2013 | 306 | 0.360 |
Why?
|
Treatment Outcome | 30 | 2024 | 64681 | 0.360 |
Why?
|
Biopsy | 9 | 2021 | 6781 | 0.350 |
Why?
|
Cardiovascular Diseases | 16 | 2024 | 15521 | 0.350 |
Why?
|
Parvovirus B19, Human | 1 | 2010 | 40 | 0.340 |
Why?
|
Cardiovascular System | 3 | 2022 | 836 | 0.340 |
Why?
|
Edema | 1 | 2014 | 764 | 0.340 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2010 | 97 | 0.330 |
Why?
|
Mitochondria, Heart | 1 | 2011 | 229 | 0.330 |
Why?
|
Radiographic Image Enhancement | 2 | 2013 | 877 | 0.330 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2021 | 152 | 0.330 |
Why?
|
Medical Oncology | 1 | 2021 | 2320 | 0.320 |
Why?
|
Perfusion Imaging | 2 | 2021 | 198 | 0.320 |
Why?
|
Pericarditis, Constrictive | 1 | 2009 | 46 | 0.320 |
Why?
|
Fluorodeoxyglucose F18 | 7 | 2024 | 2024 | 0.320 |
Why?
|
Diagnostic Imaging | 6 | 2017 | 3534 | 0.320 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2009 | 61 | 0.310 |
Why?
|
Registries | 11 | 2023 | 8246 | 0.310 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2013 | 575 | 0.310 |
Why?
|
Aortic Valve Stenosis | 3 | 2017 | 2018 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3093 | 0.310 |
Why?
|
Retrospective Studies | 29 | 2024 | 80675 | 0.310 |
Why?
|
Inflammation | 5 | 2023 | 10759 | 0.310 |
Why?
|
Proportional Hazards Models | 12 | 2014 | 12474 | 0.300 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3215 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 9 | 2020 | 6486 | 0.300 |
Why?
|
Myocardial Reperfusion | 2 | 2008 | 339 | 0.300 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 2 | 2008 | 162 | 0.300 |
Why?
|
Angina Pectoris | 5 | 2023 | 959 | 0.300 |
Why?
|
Eicosapentaenoic Acid | 2 | 2024 | 561 | 0.300 |
Why?
|
Insulin Resistance | 2 | 2019 | 3952 | 0.300 |
Why?
|
Observer Variation | 11 | 2019 | 2610 | 0.280 |
Why?
|
Organometallic Compounds | 3 | 2019 | 647 | 0.280 |
Why?
|
Sensitivity and Specificity | 16 | 2019 | 14675 | 0.280 |
Why?
|
Streptococcal Infections | 1 | 2011 | 617 | 0.280 |
Why?
|
Hypertension | 8 | 2021 | 8536 | 0.280 |
Why?
|
Coronary Thrombosis | 1 | 2010 | 440 | 0.280 |
Why?
|
Algorithms | 7 | 2015 | 14025 | 0.270 |
Why?
|
Meglumine | 2 | 2019 | 144 | 0.270 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2006 | 38 | 0.270 |
Why?
|
Adipose Tissue | 3 | 2017 | 3313 | 0.260 |
Why?
|
Pandemics | 3 | 2020 | 8663 | 0.260 |
Why?
|
Pilot Projects | 11 | 2024 | 8642 | 0.260 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2012 | 558 | 0.250 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5842 | 0.250 |
Why?
|
Double-Blind Method | 8 | 2024 | 12341 | 0.250 |
Why?
|
Renal Dialysis | 3 | 2021 | 1796 | 0.250 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2009 | 866 | 0.250 |
Why?
|
Cardiac-Gated Imaging Techniques | 3 | 2015 | 139 | 0.250 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2024 | 1725 | 0.250 |
Why?
|
Atrial Flutter | 1 | 2007 | 252 | 0.240 |
Why?
|
Cerebral Infarction | 1 | 2010 | 981 | 0.240 |
Why?
|
Fibroma | 1 | 2006 | 190 | 0.240 |
Why?
|
Myocardial Reperfusion Injury | 2 | 2023 | 480 | 0.240 |
Why?
|
Seeds | 2 | 2003 | 122 | 0.240 |
Why?
|
Heart | 6 | 2022 | 4431 | 0.240 |
Why?
|
Neoplasms | 7 | 2021 | 22142 | 0.230 |
Why?
|
Obesity | 6 | 2021 | 12940 | 0.230 |
Why?
|
Disease-Free Survival | 7 | 2018 | 6819 | 0.230 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 2 | 2003 | 286 | 0.220 |
Why?
|
Fish Oils | 2 | 2018 | 483 | 0.220 |
Why?
|
Benzylamines | 2 | 2024 | 247 | 0.220 |
Why?
|
Systole | 3 | 2017 | 936 | 0.220 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2013 | 1874 | 0.220 |
Why?
|
Uracil | 2 | 2024 | 207 | 0.220 |
Why?
|
Aortic Diseases | 1 | 2009 | 735 | 0.210 |
Why?
|
Peptide Fragments | 4 | 2024 | 5103 | 0.210 |
Why?
|
Disease Progression | 9 | 2019 | 13511 | 0.210 |
Why?
|
Purines | 2 | 2019 | 609 | 0.210 |
Why?
|
Coronary Artery Bypass | 3 | 2022 | 2193 | 0.210 |
Why?
|
Plant Proteins | 2 | 2003 | 374 | 0.210 |
Why?
|
Societies, Medical | 6 | 2020 | 3923 | 0.210 |
Why?
|
Myocardial Bridging | 1 | 2022 | 10 | 0.210 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 4 | 2022 | 323 | 0.210 |
Why?
|
Cosmetics | 1 | 2024 | 102 | 0.210 |
Why?
|
United States | 27 | 2024 | 72341 | 0.210 |
Why?
|
Organ Size | 3 | 2016 | 2253 | 0.210 |
Why?
|
Diabetes Complications | 2 | 2012 | 1316 | 0.210 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 7 | 2020 | 1130 | 0.200 |
Why?
|
Metals, Heavy | 1 | 2024 | 148 | 0.200 |
Why?
|
Consensus | 10 | 2021 | 3134 | 0.200 |
Why?
|
Hematoma | 1 | 2007 | 763 | 0.200 |
Why?
|
Ventricular Function, Right | 4 | 2023 | 618 | 0.200 |
Why?
|
Serum Amyloid P-Component | 1 | 2022 | 46 | 0.200 |
Why?
|
Arteritis | 1 | 2024 | 158 | 0.190 |
Why?
|
Genes, Regulator | 1 | 2003 | 373 | 0.190 |
Why?
|
Arterial Occlusive Diseases | 1 | 2006 | 749 | 0.190 |
Why?
|
Arabidopsis | 2 | 2003 | 466 | 0.190 |
Why?
|
Diagnosis, Differential | 9 | 2019 | 12976 | 0.190 |
Why?
|
Carboxylic Acids | 1 | 2022 | 90 | 0.190 |
Why?
|
Tongue Neoplasms | 1 | 2003 | 183 | 0.190 |
Why?
|
Recurrence | 6 | 2024 | 8457 | 0.190 |
Why?
|
Entropy | 1 | 2022 | 210 | 0.190 |
Why?
|
Endomyocardial Fibrosis | 2 | 2012 | 41 | 0.190 |
Why?
|
Atherosclerosis | 4 | 2024 | 3407 | 0.190 |
Why?
|
Mitral Valve Annuloplasty | 1 | 2022 | 144 | 0.180 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2022 | 261 | 0.170 |
Why?
|
Pyrrolidines | 1 | 2022 | 339 | 0.170 |
Why?
|
Terminology as Topic | 2 | 2019 | 1528 | 0.170 |
Why?
|
Multivariate Analysis | 7 | 2014 | 12052 | 0.170 |
Why?
|
Blood Glucose | 4 | 2014 | 6392 | 0.170 |
Why?
|
Pericardial Effusion | 1 | 2021 | 247 | 0.170 |
Why?
|
Proinsulin | 1 | 2019 | 135 | 0.170 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5493 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 677 | 0.170 |
Why?
|
Canada | 3 | 2021 | 2125 | 0.160 |
Why?
|
Exercise Tolerance | 1 | 2024 | 838 | 0.160 |
Why?
|
Freedom | 1 | 2019 | 69 | 0.160 |
Why?
|
Receptors, Mineralocorticoid | 2 | 2024 | 163 | 0.160 |
Why?
|
Mitral Valve Insufficiency | 3 | 2022 | 1400 | 0.160 |
Why?
|
Angiography | 2 | 2014 | 1597 | 0.160 |
Why?
|
Linoleic Acid | 1 | 2019 | 158 | 0.150 |
Why?
|
Aorta, Thoracic | 2 | 2015 | 1096 | 0.150 |
Why?
|
Heart Rupture | 1 | 1998 | 21 | 0.150 |
Why?
|
Arachidonic Acid | 1 | 2019 | 427 | 0.150 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 2923 | 0.150 |
Why?
|
C-Peptide | 1 | 2019 | 442 | 0.150 |
Why?
|
Equipment Safety | 1 | 2018 | 249 | 0.140 |
Why?
|
Myelodysplastic Syndromes | 3 | 2012 | 1393 | 0.140 |
Why?
|
Chronic Disease | 7 | 2024 | 9319 | 0.140 |
Why?
|
Fluorine Radioisotopes | 1 | 2020 | 420 | 0.140 |
Why?
|
Linear Models | 5 | 2015 | 5869 | 0.140 |
Why?
|
Myocytes, Cardiac | 3 | 2018 | 1666 | 0.140 |
Why?
|
Hemorrhage | 1 | 2009 | 3422 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 842 | 0.140 |
Why?
|
Mutation | 7 | 2016 | 30004 | 0.140 |
Why?
|
Heart Defects, Congenital | 4 | 2015 | 4673 | 0.140 |
Why?
|
Cohort Studies | 8 | 2023 | 41496 | 0.140 |
Why?
|
Young Adult | 16 | 2019 | 59222 | 0.140 |
Why?
|
Vasodilation | 2 | 2019 | 966 | 0.130 |
Why?
|
Ferrosoferric Oxide | 1 | 2017 | 348 | 0.130 |
Why?
|
Evidence-Based Medicine | 5 | 2021 | 3691 | 0.130 |
Why?
|
ROC Curve | 4 | 2015 | 3584 | 0.130 |
Why?
|
Internationality | 1 | 2022 | 999 | 0.130 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8002 | 0.130 |
Why?
|
Angina, Unstable | 3 | 2020 | 890 | 0.130 |
Why?
|
RNA, Small Nucleolar | 1 | 2016 | 27 | 0.130 |
Why?
|
Infection Control | 2 | 2020 | 983 | 0.130 |
Why?
|
Transplantation Conditioning | 3 | 2012 | 1591 | 0.130 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2017 | 278 | 0.130 |
Why?
|
Patient Selection | 6 | 2019 | 4246 | 0.130 |
Why?
|
Radiography | 5 | 2011 | 6974 | 0.130 |
Why?
|
Pyrazoles | 2 | 2019 | 2010 | 0.130 |
Why?
|
Pulmonary Artery | 2 | 2015 | 1929 | 0.130 |
Why?
|
Aorta | 1 | 2023 | 2040 | 0.130 |
Why?
|
Aortic Valve | 2 | 2016 | 1959 | 0.130 |
Why?
|
Hemodynamics | 3 | 2016 | 4165 | 0.130 |
Why?
|
Societies, Scientific | 1 | 2017 | 223 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2022 | 58952 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2018 | 12159 | 0.130 |
Why?
|
Chi-Square Distribution | 4 | 2016 | 3418 | 0.120 |
Why?
|
Survival Rate | 4 | 2014 | 12728 | 0.120 |
Why?
|
Electric Countershock | 1 | 2018 | 533 | 0.120 |
Why?
|
Echocardiography, Transesophageal | 4 | 2020 | 1086 | 0.120 |
Why?
|
Body Water | 2 | 2013 | 340 | 0.120 |
Why?
|
Extracellular Space | 2 | 2013 | 563 | 0.120 |
Why?
|
Pentalogy of Cantrell | 1 | 2014 | 1 | 0.120 |
Why?
|
Myeloablative Agonists | 2 | 2012 | 209 | 0.120 |
Why?
|
Ventricular Premature Complexes | 1 | 2015 | 112 | 0.120 |
Why?
|
Adiposity | 3 | 2017 | 1879 | 0.120 |
Why?
|
Decision Support Techniques | 2 | 2016 | 2004 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 761 | 0.120 |
Why?
|
Plethysmography, Impedance | 1 | 2014 | 42 | 0.120 |
Why?
|
Diltiazem | 1 | 2014 | 131 | 0.120 |
Why?
|
Recovery of Function | 3 | 2014 | 2981 | 0.110 |
Why?
|
Calcinosis | 3 | 2009 | 1477 | 0.110 |
Why?
|
Lymphoma | 1 | 2023 | 1898 | 0.110 |
Why?
|
Boston | 3 | 2011 | 9327 | 0.110 |
Why?
|
Scimitar Syndrome | 1 | 2014 | 30 | 0.110 |
Why?
|
Stem Cell Transplantation | 2 | 2012 | 1600 | 0.110 |
Why?
|
Transcription Factors | 3 | 2003 | 12101 | 0.110 |
Why?
|
Echocardiography, Stress | 1 | 2014 | 135 | 0.110 |
Why?
|
Nausea | 1 | 2016 | 678 | 0.110 |
Why?
|
Heart Rate | 2 | 2015 | 4197 | 0.110 |
Why?
|
Wireless Technology | 1 | 2014 | 98 | 0.110 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2020 | 1351 | 0.110 |
Why?
|
Respiratory Rate | 1 | 2014 | 176 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2021 | 8998 | 0.100 |
Why?
|
Diastole | 2 | 2014 | 782 | 0.100 |
Why?
|
Docosahexaenoic Acids | 1 | 2019 | 906 | 0.100 |
Why?
|
Incidence | 5 | 2020 | 21366 | 0.100 |
Why?
|
Streptococcus intermedius | 1 | 2011 | 3 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.100 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2014 | 187 | 0.100 |
Why?
|
Chelation Therapy | 1 | 2012 | 77 | 0.100 |
Why?
|
Hydrochlorothiazide | 2 | 2014 | 94 | 0.100 |
Why?
|
Lysosomal Storage Diseases | 1 | 2012 | 78 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 3446 | 0.100 |
Why?
|
Athletes | 1 | 2019 | 1138 | 0.100 |
Why?
|
Forecasting | 2 | 2020 | 2928 | 0.100 |
Why?
|
Abscess | 1 | 2015 | 605 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1427 | 0.090 |
Why?
|
Troponin T | 1 | 2016 | 780 | 0.090 |
Why?
|
Blood Pressure | 5 | 2021 | 8479 | 0.090 |
Why?
|
Radiosurgery | 1 | 2021 | 1339 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 691 | 0.090 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
Feasibility Studies | 4 | 2014 | 5250 | 0.090 |
Why?
|
Magnetics | 1 | 2014 | 598 | 0.090 |
Why?
|
Endocarditis, Bacterial | 1 | 2015 | 436 | 0.090 |
Why?
|
Bone Marrow Transplantation | 2 | 2010 | 2692 | 0.090 |
Why?
|
Capillary Permeability | 1 | 2014 | 773 | 0.090 |
Why?
|
Enalapril | 3 | 2018 | 310 | 0.090 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 42 | 0.090 |
Why?
|
Blood Circulation | 1 | 2011 | 248 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1185 | 0.090 |
Why?
|
Advisory Committees | 1 | 2015 | 788 | 0.090 |
Why?
|
Metoprolol | 1 | 2011 | 90 | 0.090 |
Why?
|
Sex Factors | 4 | 2024 | 10553 | 0.090 |
Why?
|
Heterozygote | 2 | 2014 | 2778 | 0.090 |
Why?
|
Syncope | 2 | 2010 | 428 | 0.090 |
Why?
|
Disease Models, Animal | 8 | 2016 | 18222 | 0.090 |
Why?
|
Heart Aneurysm | 1 | 2010 | 114 | 0.090 |
Why?
|
Erythrocytes | 1 | 2019 | 2413 | 0.090 |
Why?
|
Microvessels | 1 | 2014 | 580 | 0.090 |
Why?
|
Acute Disease | 4 | 2012 | 7226 | 0.090 |
Why?
|
Carotid Arteries | 1 | 2014 | 941 | 0.090 |
Why?
|
Procollagen | 1 | 2010 | 187 | 0.090 |
Why?
|
Doxorubicin | 1 | 2016 | 2224 | 0.090 |
Why?
|
Odds Ratio | 4 | 2016 | 9652 | 0.080 |
Why?
|
Artifacts | 3 | 2024 | 1912 | 0.080 |
Why?
|
Heterocyclic Compounds | 1 | 2010 | 245 | 0.080 |
Why?
|
Intra-Abdominal Fat | 1 | 2014 | 612 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2014 | 1504 | 0.080 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2012 | 477 | 0.080 |
Why?
|
Telemetry | 1 | 2010 | 199 | 0.080 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2009 | 46 | 0.080 |
Why?
|
Diuretics | 2 | 2014 | 611 | 0.080 |
Why?
|
Arabidopsis Proteins | 2 | 2003 | 264 | 0.080 |
Why?
|
Chagas Cardiomyopathy | 1 | 2009 | 71 | 0.080 |
Why?
|
Models, Cardiovascular | 3 | 2015 | 983 | 0.080 |
Why?
|
Tomography, Emission-Computed | 1 | 2012 | 1123 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2014 | 3201 | 0.080 |
Why?
|
Fabry Disease | 1 | 2009 | 87 | 0.080 |
Why?
|
Foreign-Body Migration | 1 | 2010 | 220 | 0.080 |
Why?
|
Ischemia | 3 | 2022 | 1889 | 0.080 |
Why?
|
Prevalence | 4 | 2016 | 15721 | 0.080 |
Why?
|
European Union | 1 | 2009 | 157 | 0.080 |
Why?
|
Aldosterone | 1 | 2013 | 869 | 0.080 |
Why?
|
Logistic Models | 4 | 2014 | 13249 | 0.070 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 2019 | 0.070 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2016 | 1555 | 0.070 |
Why?
|
Mitral Valve | 2 | 2022 | 1465 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2003 | 4021 | 0.070 |
Why?
|
Heart Valve Prosthesis | 1 | 2016 | 1463 | 0.070 |
Why?
|
Age Factors | 4 | 2019 | 18384 | 0.070 |
Why?
|
Vena Cava Filters | 1 | 2010 | 261 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2018 | 2877 | 0.070 |
Why?
|
Paraganglioma | 1 | 2009 | 143 | 0.070 |
Why?
|
Collagen | 2 | 2013 | 2635 | 0.070 |
Why?
|
Cardiac Surgical Procedures | 3 | 2011 | 3627 | 0.070 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 1221 | 0.070 |
Why?
|
Capillaries | 1 | 2010 | 755 | 0.070 |
Why?
|
Swine | 3 | 2014 | 5909 | 0.070 |
Why?
|
Radioisotopes | 1 | 2008 | 502 | 0.070 |
Why?
|
Hypotension | 2 | 2017 | 879 | 0.070 |
Why?
|
HIV Infections | 2 | 2024 | 17348 | 0.070 |
Why?
|
Embolism | 1 | 2010 | 399 | 0.070 |
Why?
|
Carotid Stenosis | 1 | 2014 | 859 | 0.070 |
Why?
|
Massachusetts | 3 | 2014 | 8837 | 0.070 |
Why?
|
Prostheses and Implants | 1 | 2014 | 1273 | 0.070 |
Why?
|
Pericardiocentesis | 1 | 2007 | 78 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3412 | 0.070 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7400 | 0.070 |
Why?
|
Delphi Technique | 2 | 2021 | 848 | 0.070 |
Why?
|
Equipment Design | 3 | 2014 | 3510 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2003 | 9567 | 0.070 |
Why?
|
Adolescent | 13 | 2018 | 88300 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2016 | 22174 | 0.070 |
Why?
|
Life Tables | 1 | 2006 | 364 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2014 | 1003 | 0.070 |
Why?
|
Nuclear Medicine | 2 | 2019 | 257 | 0.060 |
Why?
|
Aging | 2 | 2016 | 8702 | 0.060 |
Why?
|
Cardiac Tamponade | 1 | 2007 | 175 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2013 | 1405 | 0.060 |
Why?
|
RNA, Plant | 2 | 2003 | 30 | 0.060 |
Why?
|
Sleep Apnea Syndromes | 1 | 2014 | 977 | 0.060 |
Why?
|
Iron | 2 | 2012 | 1791 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2012 | 3610 | 0.060 |
Why?
|
Asymptomatic Diseases | 2 | 2020 | 588 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1416 | 0.060 |
Why?
|
Prosthesis Failure | 1 | 2010 | 1204 | 0.060 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2010 | 607 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9187 | 0.060 |
Why?
|
Blood Flow Velocity | 2 | 2018 | 1375 | 0.060 |
Why?
|
Sheep | 3 | 2014 | 1436 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4107 | 0.060 |
Why?
|
Gene Expression Regulation, Plant | 2 | 2003 | 211 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6223 | 0.060 |
Why?
|
Survivors | 1 | 2015 | 2369 | 0.060 |
Why?
|
Body Mass Index | 4 | 2014 | 12952 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 4 | 2015 | 4052 | 0.060 |
Why?
|
Autoimmunity | 1 | 2012 | 1356 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2636 | 0.060 |
Why?
|
Animals | 17 | 2020 | 168089 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1518 | 0.060 |
Why?
|
Creatine Kinase | 1 | 2006 | 684 | 0.060 |
Why?
|
MicroRNAs | 2 | 2018 | 3758 | 0.060 |
Why?
|
Sex Characteristics | 2 | 2024 | 2640 | 0.060 |
Why?
|
NG-Nitroarginine Methyl Ester | 2 | 2014 | 260 | 0.050 |
Why?
|
Hearing Loss | 1 | 2011 | 782 | 0.050 |
Why?
|
Phenotype | 4 | 2016 | 16575 | 0.050 |
Why?
|
Calcium | 2 | 2009 | 5719 | 0.050 |
Why?
|
Longitudinal Studies | 3 | 2016 | 14610 | 0.050 |
Why?
|
E2F1 Transcription Factor | 1 | 2003 | 178 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9458 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2003 | 7865 | 0.050 |
Why?
|
Rheumatic Heart Disease | 1 | 2024 | 163 | 0.050 |
Why?
|
Lipomatosis | 1 | 2004 | 112 | 0.050 |
Why?
|
Genome, Human | 1 | 2016 | 4423 | 0.050 |
Why?
|
E2F Transcription Factors | 1 | 2003 | 269 | 0.050 |
Why?
|
Weight Loss | 1 | 2014 | 2680 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 1592 | 0.050 |
Why?
|
Ultrasonography | 2 | 2007 | 5969 | 0.050 |
Why?
|
Fever | 1 | 2010 | 1618 | 0.050 |
Why?
|
Research Design | 2 | 2017 | 6180 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3239 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4321 | 0.050 |
Why?
|
Exercise | 2 | 2016 | 5874 | 0.050 |
Why?
|
Dyspnea | 1 | 2010 | 1347 | 0.050 |
Why?
|
Electrodes | 2 | 2015 | 611 | 0.050 |
Why?
|
Lip | 1 | 2024 | 197 | 0.050 |
Why?
|
Hospitalization | 4 | 2024 | 10707 | 0.050 |
Why?
|
Genetic Testing | 1 | 2015 | 3537 | 0.050 |
Why?
|
Disease Management | 1 | 2012 | 2507 | 0.050 |
Why?
|
Pattern Recognition, Automated | 1 | 2008 | 993 | 0.050 |
Why?
|
Drug Therapy, Combination | 4 | 2022 | 6304 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2020 | 2329 | 0.050 |
Why?
|
Carcinogens | 1 | 2024 | 452 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2003 | 451 | 0.050 |
Why?
|
Equipment Failure Analysis | 2 | 2014 | 846 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6345 | 0.050 |
Why?
|
Radiation Dosage | 1 | 2010 | 1962 | 0.050 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 1549 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2003 | 628 | 0.050 |
Why?
|
Adenosine | 1 | 2006 | 805 | 0.050 |
Why?
|
Analgesics | 1 | 1988 | 1068 | 0.050 |
Why?
|
Risk | 2 | 2009 | 9616 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2270 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2003 | 2740 | 0.050 |
Why?
|
Ligation | 2 | 2012 | 446 | 0.040 |
Why?
|
Survival Analysis | 3 | 2010 | 10088 | 0.040 |
Why?
|
Catheterization | 1 | 2006 | 1428 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 697 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2007 | 973 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15920 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2012 | 3417 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2016 | 17897 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2003 | 671 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2003 | 991 | 0.040 |
Why?
|
Multigene Family | 1 | 2003 | 1075 | 0.040 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 244 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1664 | 0.040 |
Why?
|
Troponin | 1 | 2003 | 504 | 0.040 |
Why?
|
Respiration | 1 | 2006 | 1657 | 0.040 |
Why?
|
Thrombosis | 2 | 2017 | 2944 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2018 | 26072 | 0.040 |
Why?
|
In Situ Hybridization | 1 | 2003 | 1900 | 0.040 |
Why?
|
Europe | 2 | 2016 | 3423 | 0.040 |
Why?
|
Goals | 1 | 2024 | 710 | 0.040 |
Why?
|
Taxoids | 1 | 2002 | 668 | 0.040 |
Why?
|
Ferritins | 2 | 2012 | 596 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2022 | 1097 | 0.040 |
Why?
|
Genes, Plant | 1 | 1998 | 128 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 620 | 0.040 |
Why?
|
Quality of Life | 5 | 2020 | 13367 | 0.040 |
Why?
|
Lead | 1 | 2024 | 879 | 0.040 |
Why?
|
Palliative Care | 3 | 2002 | 3599 | 0.040 |
Why?
|
Cell Survival | 1 | 2008 | 5778 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2015 | 1490 | 0.040 |
Why?
|
Tremor | 3 | 1988 | 190 | 0.040 |
Why?
|
China | 1 | 2024 | 2374 | 0.040 |
Why?
|
RNA, Small Untranslated | 1 | 2018 | 77 | 0.040 |
Why?
|
Hypertrophy | 2 | 2013 | 558 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2023 | 788 | 0.040 |
Why?
|
Rheumatic Diseases | 1 | 2024 | 654 | 0.040 |
Why?
|
Environmental Monitoring | 1 | 2024 | 1460 | 0.040 |
Why?
|
Edema, Cardiac | 1 | 2016 | 19 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2012 | 5666 | 0.030 |
Why?
|
Terminal Care | 1 | 1988 | 1760 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2020 | 2263 | 0.030 |
Why?
|
HIV | 1 | 2023 | 1581 | 0.030 |
Why?
|
Comorbidity | 2 | 2012 | 10516 | 0.030 |
Why?
|
Thalamic Nuclei | 2 | 1988 | 111 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1610 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 850 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11101 | 0.030 |
Why?
|
Urinary Calculi | 1 | 1996 | 90 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16954 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2003 | 13402 | 0.030 |
Why?
|
X-Ray Diffraction | 1 | 1996 | 418 | 0.030 |
Why?
|
Phylogeny | 1 | 2003 | 2809 | 0.030 |
Why?
|
Inflammation Mediators | 2 | 2014 | 1885 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2017 | 426 | 0.030 |
Why?
|
Simvastatin | 1 | 2017 | 346 | 0.030 |
Why?
|
Digoxin | 1 | 1995 | 246 | 0.030 |
Why?
|
Body Weight | 2 | 2017 | 4618 | 0.030 |
Why?
|
Immunoglobulin Variable Region | 1 | 1995 | 419 | 0.030 |
Why?
|
Paclitaxel | 1 | 2002 | 1730 | 0.030 |
Why?
|
Glycolysis | 1 | 2018 | 836 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2006 | 1920 | 0.030 |
Why?
|
Iohexol | 1 | 2015 | 205 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2022 | 2410 | 0.030 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 17598 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2017 | 982 | 0.030 |
Why?
|
Scattering, Radiation | 1 | 1996 | 490 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 790 | 0.030 |
Why?
|
Mice | 7 | 2020 | 81330 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2897 | 0.030 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 1995 | 445 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1812 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 518 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 807 | 0.030 |
Why?
|
Temperature | 1 | 2020 | 2219 | 0.030 |
Why?
|
Child, Preschool | 5 | 2015 | 42225 | 0.030 |
Why?
|
Veins | 1 | 2017 | 767 | 0.030 |
Why?
|
Aortography | 1 | 2015 | 421 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7407 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20982 | 0.030 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2014 | 190 | 0.030 |
Why?
|
Arteries | 1 | 2017 | 1121 | 0.030 |
Why?
|
Transplantation, Homologous | 2 | 2012 | 4822 | 0.030 |
Why?
|
Sheep, Domestic | 1 | 2012 | 50 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
Parkinson Disease | 4 | 1988 | 2867 | 0.030 |
Why?
|
Patient Education as Topic | 2 | 2012 | 2317 | 0.030 |
Why?
|
Bacteriophages | 1 | 1995 | 378 | 0.030 |
Why?
|
Thalamus | 3 | 1989 | 1046 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2513 | 0.020 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 69 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2015 | 1498 | 0.020 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1655 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2013 | 518 | 0.020 |
Why?
|
Deferoxamine | 1 | 2012 | 155 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 492 | 0.020 |
Why?
|
Models, Economic | 1 | 2016 | 714 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2003 | 3596 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2018 | 2706 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2012 | 318 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 625 | 0.020 |
Why?
|
Myocardial Stunning | 1 | 2011 | 67 | 0.020 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 459 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 911 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1423 | 0.020 |
Why?
|
Troponin I | 1 | 2014 | 652 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2010 | 151 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2015 | 26200 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2014 | 1435 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 459 | 0.020 |
Why?
|
Cardiac Myosins | 1 | 2010 | 128 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2553 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2003 | 11067 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1751 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15637 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2017 | 1506 | 0.020 |
Why?
|
Carrier Proteins | 2 | 2014 | 4935 | 0.020 |
Why?
|
Smoking | 1 | 2006 | 9055 | 0.020 |
Why?
|
Dipyridamole | 1 | 2009 | 142 | 0.020 |
Why?
|
Comprehension | 1 | 2014 | 619 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1838 | 0.020 |
Why?
|
Random Allocation | 1 | 2013 | 2393 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2465 | 0.020 |
Why?
|
Myosin Heavy Chains | 1 | 2010 | 403 | 0.020 |
Why?
|
Dosage Forms | 1 | 1988 | 56 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7386 | 0.020 |
Why?
|
3-Iodobenzylguanidine | 1 | 2009 | 115 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 352 | 0.020 |
Why?
|
Wisconsin | 1 | 1988 | 122 | 0.020 |
Why?
|
Biofeedback, Psychology | 1 | 1989 | 116 | 0.020 |
Why?
|
Ticlopidine | 1 | 2012 | 730 | 0.020 |
Why?
|
Dogs | 1 | 2012 | 3832 | 0.020 |
Why?
|
Stereotaxic Techniques | 2 | 1987 | 555 | 0.020 |
Why?
|
Models, Statistical | 2 | 2015 | 5081 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2217 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2854 | 0.020 |
Why?
|
Collagen Type I | 1 | 2010 | 616 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1241 | 0.020 |
Why?
|
Whole Body Imaging | 1 | 2009 | 282 | 0.020 |
Why?
|
Injections | 1 | 2010 | 832 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2010 | 767 | 0.020 |
Why?
|
Renal Circulation | 1 | 2007 | 291 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 22128 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2019 | 3410 | 0.020 |
Why?
|
Physical Examination | 1 | 2012 | 1255 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3594 | 0.020 |
Why?
|
Electromyography | 3 | 1988 | 1393 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2011 | 901 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 1111 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 961 | 0.020 |
Why?
|
Vascular Resistance | 1 | 2009 | 933 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1848 | 0.020 |
Why?
|
Reference Values | 1 | 2013 | 4921 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4420 | 0.020 |
Why?
|
Stents | 1 | 2017 | 3177 | 0.020 |
Why?
|
Systems Integration | 1 | 2007 | 428 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 2457 | 0.020 |
Why?
|
Device Removal | 1 | 2010 | 629 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7512 | 0.020 |
Why?
|
Prosthesis Implantation | 1 | 2010 | 590 | 0.020 |
Why?
|
Brachial Artery | 1 | 2007 | 366 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2112 | 0.010 |
Why?
|
Child | 4 | 2015 | 80154 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2007 | 518 | 0.010 |
Why?
|
Internet | 1 | 2017 | 3096 | 0.010 |
Why?
|
Tricuspid Valve | 1 | 2007 | 410 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5333 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3634 | 0.010 |
Why?
|
Lipids | 1 | 2014 | 3331 | 0.010 |
Why?
|
Prosthesis Design | 1 | 2010 | 2114 | 0.010 |
Why?
|
Autoantibodies | 1 | 2012 | 2119 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 5321 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3688 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2012 | 2380 | 0.010 |
Why?
|
Albuminuria | 1 | 2007 | 656 | 0.010 |
Why?
|
Feedback | 1 | 1987 | 790 | 0.010 |
Why?
|
Potassium | 1 | 2007 | 1309 | 0.010 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1535 | 0.010 |
Why?
|
Cost of Illness | 1 | 2012 | 1936 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2374 | 0.010 |
Why?
|
Infant | 2 | 2015 | 36170 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8531 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6774 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3821 | 0.010 |
Why?
|
Cloning, Molecular | 2 | 1998 | 4167 | 0.010 |
Why?
|
Central Nervous System | 1 | 1989 | 1333 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2007 | 2928 | 0.010 |
Why?
|
Health Status | 1 | 2014 | 4077 | 0.010 |
Why?
|
Oxygen | 1 | 2012 | 4228 | 0.010 |
Why?
|
Health Behavior | 1 | 2012 | 2641 | 0.010 |
Why?
|
Life Style | 1 | 2012 | 3907 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2007 | 2082 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2012 | 2056 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 2746 | 0.010 |
Why?
|
Models, Neurological | 1 | 1989 | 1769 | 0.010 |
Why?
|
Action Potentials | 1 | 1988 | 1830 | 0.010 |
Why?
|
Administration, Oral | 1 | 1988 | 4015 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2012 | 4027 | 0.010 |
Why?
|
Macrophages | 1 | 2014 | 5755 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3025 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4788 | 0.010 |
Why?
|
Bleomycin | 1 | 1980 | 495 | 0.010 |
Why?
|
Vinblastine | 1 | 1980 | 488 | 0.010 |
Why?
|
Plants, Genetically Modified | 1 | 1998 | 114 | 0.010 |
Why?
|
Peptides | 1 | 2010 | 4353 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2691 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11855 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1998 | 849 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2002 | 13386 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10218 | 0.010 |
Why?
|
Heart Valve Diseases | 1 | 2003 | 1031 | 0.010 |
Why?
|
Radiotherapy | 1 | 2002 | 1500 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6224 | 0.010 |
Why?
|
Cisplatin | 1 | 1980 | 1652 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1980 | 801 | 0.010 |
Why?
|
Depression | 1 | 2012 | 8132 | 0.010 |
Why?
|
Mutagenesis | 1 | 1995 | 1226 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2814 | 0.010 |
Why?
|
Neurons | 2 | 1987 | 9429 | 0.010 |
Why?
|
Antibodies | 1 | 1995 | 2415 | 0.000 |
Why?
|
Stochastic Processes | 1 | 1989 | 355 | 0.000 |
Why?
|
Binding Sites | 1 | 1995 | 5988 | 0.000 |
Why?
|
Base Sequence | 1 | 1995 | 12404 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1998 | 12747 | 0.000 |
Why?
|
Cell Line | 1 | 1995 | 15545 | 0.000 |
Why?
|
Muscles | 1 | 1985 | 1568 | 0.000 |
Why?
|
Leukopenia | 1 | 1980 | 213 | 0.000 |
Why?
|
Evoked Potentials | 1 | 1985 | 1047 | 0.000 |
Why?
|
Synaptic Transmission | 1 | 1985 | 1167 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1980 | 1182 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1980 | 1201 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1980 | 4909 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1980 | 11119 | 0.000 |
Why?
|